Dengue Fever News and Research

RSS

Dengue fever is a mosquito-borne tropical disease caused by the dengue virus. Symptoms typically begin three to fourteen days after infection. These may include a high fever, headache, vomiting, muscle and joint pains, and a characteristic skin rash.

Entomologists to develop genetically engineered bacteria for killing mosquito larvae

Roughly half the world's population still lives in areas at risk of malaria transmission. Even in the United States, 1500 cases of malaria are reported annually on average.

15 Jun 2010

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant efficacy in the recently completed preliminary cell culture studies. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

2 Jun 2010

HZI researchers develop new method to produce insulin for treatment of diabetes

More than eight million diabetics live in Germany. Diabetes is not restricted to our prosperous society and the highest growth rates often occur in countries with aspiring economies such as in Asia. Worldwide, more than 285 million people suffer from this illness; with 50 million diabetics, India is the country with the most people affected by this disease.

27 May 2010

NanoViricides reports $2.95M in cash, $305,000 in prepaid expenses for quarter ended March 31, 2010

NanoViricides, Inc., has filed its quarterly report with the Securities and Exchange Commission on Thursday, May 20th, in a timely fashion.

24 May 2010

Saint Louis University conducts research to find safe, effective vaccination for dengue

Sponsored by the National Institutes of Health, Saint Louis University's Center for Vaccine Development is conducting research of an investigational vaccine designed to prevent people from contracting dengue, a potentially lethal virus that has rapidly spread around the world.

20 May 2010

Inviragen initiates first clinical trial of DENVax vaccine to protect against dengue fever

Inviragen has announced the initiation of the first clinical trial of its vaccine to protect against dengue fever. The trial, to be conducted at Saint Louis University, is designed to assess the safety of Inviragen's investigational dengue vaccine.

20 May 2010

Novartis employees organise events to contribute to community organizations

In a spring tradition that has become well entrenched at the company over the past 14 years, employees of Novartis from across Canada are today joining their colleagues around the world in taking time away from their work to contribute to community organizations.

15 May 2010

Chimerix commences first-in-human study of CMX157 for HIV

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.

14 May 2010

New study may help design better vaccines for dengue fever

Some of the human immune system's defences against the virus that causes dengue fever actually help the virus to infect more cells, according to new research published today in the journal Science.

7 May 2010

A*STAR's BMRC and SIgN award grants for twelve research projects on infectious diseases and immunology

Twelve research projects on infectious diseases and immunology have been awarded grants by A*STAR's Biomedical Research Council (BMRC) and Singapore Immunology Network (SIgN) this year.

21 Apr 2010

Checklist to stay healthy and active during summer season

There are millions of vacation destinations to visit this summer and thousands of sights to see, but there is one surefire way to ruin your trip -- getting sick. Although you may not be thinking about viruses and bacterial infections when you plan your trip, there are a few nasty bugs you should be aware of as you pack your bags.

13 Apr 2010

Emory Institute of Drug Discovery and Zirus collaborate to develop new anti-viral drugs

The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.

30 Mar 2010

Inovio Biomedical's total revenue increased to $2.6M for quarter ended December 31, 2009

Inovio Biomedical Corporation today reported financial results for the quarter and year ended December 31, 2009.

29 Mar 2010

Bonis project develops multimedia system to identify dengue plague and febrile illnesses in Paraguay

Xabier Basogain Olabe (Donostia-San Sebasti-n, 1962), lecturer at the Higher Technical School of Engineering in Bilbao, is leading this project, known as Bonis. It involves developing a multimedia system in order to undertake visual monitoring of epidemiology in isolated areas of Paraguay and thus avoid the dengue plague and other febrile illnesses.

29 Mar 2010

PAHO documents increase in dengue fever cases in Latin America

Countries in Latin America "are bracing this year for a particularly virulent outbreak of the mosquito-borne tropical disease" known as dengue fever, after reports show an increase in the number of cases recorded this year, Agence France-Presse reports. "The Pan-American Health Organization (PAHO) said so far it has logged some 146,000 cases in the first three months of the year, of which 79 have been fatal. This time last year there were some 79,000 cases of dengue reported, with 26 deaths," the news service writes.

26 Mar 2010

International symposium to feature latest findings on vector-borne diseases in humans and plants

Leading insect vector biologists from around the world will gather at the University of California, Riverside for two days this month to discuss their latest research on vector-borne diseases in humans and plants.

16 Mar 2010

Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients who are seropositive for cytomegalovirus (CMV).

9 Mar 2010

PDVI launches new web site for tracking dengue fever epidemics

PDVI, a program of the International Vaccine Institute funded by the Bill & Melinda Gates Foundation, announces today the launch of http://www.denguewatch.org, a news hub for tracking dengue fever epidemics worldwide.

9 Mar 2010

Investigators disprove reports that well-fed children are more vulnerable to dengue virus

A new study led by St. Jude Children's Research Hospital investigators disproves reports that well-fed children are more vulnerable to the dengue virus. Mosquitoes spread the virus, which can cause severe flu-like symptoms and sometimes lethal complications.

5 Mar 2010

Cornell researchers find new protein that may help control mosquitoes from spreading diseases

Cornell researchers have found a protein that may lead to a new way to control mosquitoes that spread dengue fever, yellow fever and other diseases when they feed on humans: Prevent them from urinating as they feed on blood.

4 Mar 2010